Portfolio Lab

Globus Medical Inc

  • Stock
  • Ticker GMED
  • ISIN US3795772082
  • NYSE

Health care · Medical technology · USA

$66.89 −2.49%
Close of 20 Nov 2026
Open in backtest

Performance, volatility and drawdowns of Globus Medical Inc since 11/2016, with distributions reinvested and calculated in US dollars. As of 20 Nov 2026.

Performance

GMEDGlobal equities (VT)

$10,000 grew to $31,199. Global equities (VT): $29,042.

Distributions reinvested, before taxes and brokerage costs. Dashed: Global equities (VT) for comparison.

Declines from the peak

Lowest point −47.9% in 11/2023, measured from the peak in 09/2021. It took 38 months to get back to the old peak.

1-year return
−18.7%
5-year return p.a.
−0.2%
10-year return p.a.
+12.1%
Volatility p.a.
35.7%
Largest decline
−47.9%

Financial statements

Amounts in $ millions from filings with the SEC, earnings per share in $; fourth quarter and quarterly cash flow derived from year-to-date figures

Quarter end12/202403/202506/202509/202512/202503/202606/202609/2026
Income statement
Revenue657598745769826760790764
Gross profit394403497517565526548531
Operating income609776137169150182178
EBITDA128163117179239220223219
Net income2775203119141124152141
Earnings per share0.190.541.490.881.020.901.101.04
Balance sheet
Total assets5,2524,7114,9615,0965,3035,4405,4885,528
Liabilities1,074623665697730707720732
Equity4,1774,0884,2964,3994,5734,7324,7694,796
Cash784461229372526561508441
Cash flow
Operating cash flow21017778250249202210265
Capital expenditure-17-36-47-36-46-40-33-40
Free cash flow19314131214202163177225

Value it:DCF calculatorMultiples calculator

Annual returns

Best year 2017 at +65.7%, weakest 2023 at −28.2%. 8 of 9 full years were positive. * partial year.

Quarterly reports

Filing date with the SEC and earnings per share of the quarter

DayEarnings per share
5 Nov 2026$1.04
6 Aug 2026$1.10
7 May 2026$0.90
24 Feb 2026$1.02
6 Nov 2025$0.88
7 Aug 2025$1.49
8 May 2025$0.54
20 Feb 2025$0.19
5 Nov 2024$0.38
6 Aug 2024$0.23
7 May 2024−$0.05
21 Feb 2024$0.09

Key metrics

Metrics of 15 Nov 2026; P/E, P/B, P/S, market cap and dividend yield at the last close.

Valuation

Market cap
€8.2bn
Market cap in trading currency
$9.10bn
Enterprise value
$8.58bn
P/E
16.5
P/S
2.90
P/B
1.90
EV/Sales
2.73
EV/EBITDA
9.5
Earnings yield
6.1%
FCF yield
8.4%

Results (last four quarters)

Revenue
$3.14bn
Gross profit
$2.17bn
EBITDA
$901m
Net income
$558m
Earnings per share
$4.06
Revenue per share
$23.08
Revenue growth
−0.7%
Earnings growth
+18.7%

Profitability

Gross margin
69.1%
Operating margin
21.6%
Net margin
17.8%
Return on equity
12.1%
Return on assets
10.1%

Balance sheet and cash flow

Cash
$517m
Cash per share
$3.80
Financial debt
–
Debt/equity %
–
Current ratio
4.30
Book value per share
$35.26
Operating cash flow
$926m
Free cash flow
$767m

Dividend

Dividend yield
0.00%
Dividend (12 months)
$0.00
Yield (12 months)
0.00%
Payout ratio
0%
Ex-dividend date
–

Shares and trading

Shares outstanding
136m
Volume
1.51m
Avg. volume 3 months
1.61m
Relative volume
0.9

Price and technicals

Price
$66.89
1 day
−2.5%
52-week high
$96.82
52-week low
$66.89
Distance to 52-week high
−30.9%
Distance to 52-week low
0.0%
Distance to 50-day line
−12.0%
Distance to 200-day line
−18.6%
RSI (14)
35
Volatility 1M
73.8%

Performance

1 week
−7.3%
1 month
−18.1%
3 months
−20.4%
6 months
−21.1%
YTD
−23.4%
1 year
−20.2%

Dates

Fiscal year end
31 Dec 2025
Most recent quarter
30 Sep 2026

Frequently asked questions

How has GMED performed since 11/2016?

$10,000 grew to $31,199 by 20 Nov 2026, which is +12.1% per year. Distributions are reinvested; taxes and brokerage costs are not deducted.

How volatile is GMED?

Volatility was 35.7% per year, measured on monthly returns. The largest decline from a peak was −47.9%, with the low in 11/2023.

How does GMED compare with a broad equity ETF?

Over the same period Global equities (VT) returned +11.3% per year at 15.1% volatility, GMED returned +12.1% at 35.7%. The correlation of monthly returns was 0.47; 1 would mean they moved in lockstep.

Which currency are the figures in?

In US dollars, the currency of the US listing.

Not investment advice. Metrics and financial statements calculated from the company's mandatory filings with the SEC, without guarantee; amounts in US dollars.

Reference data of securities: source ESMA (FIRDS reference data) and SEC (EDGAR).

Not investment advice: results in Portfolio Lab are model calculations based on historical data and your inputs. Past performance is not a reliable indicator of future results.

Globus Medical Inc (GMED): Return and risk | Portfolio Lab